Abstract: The invention concerns the two pure human granulocyte L1 proteins of pI 6.3 and pI 6.5, and mixtures thereof, methods for their isolation and purification, their use as marker proteins and antigenics, antisera produced against these proteins, methods for producing said antisera, the use of said antisera for the qualitative and quantitative determinatoin of L1 proteins, and test kits comprising said antisera.

Abstract: The invention relates to novel monoclonal antibodies having a high affinity for human renin, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, and to processes for the preparation of said hybridoma cells lines. The monoclonal antibodies according to the invention and their derivatives can be used for the qualitative and quantitative determination of human renin and structurally similar renin, for the purification of human renin and structurally similar renin and for the treatment of high blood pressure and cardiac insufficiency.

Abstract: The invention relates to a novel microorganism of the genus Rhodococcus, to the use thereof in a process for the microbiological degradation of amino-s-triazines and cyanuric acid in wastewaters, as well as to a process for the microbiological degradation of s-triazine derivatives to biomass or to degradation products such as NH.sup.30.sub.4 and/or chloride, which comprises the combined use of said microorganism with Pseudomonas spp.

Abstract: The present invention relates to desulfatohirudins, to the preparation thereof, to pharmaceutical compositions containing these compounds, and to the use thereof.The desulfatohirudins of this invention correspond to hirudin in biological activity and are therefore particularly useful for inhibiting blood clotting.

Abstract: The invention relates to novel benzodioxole derivatives of the general formula I ##STR1## in which R.sub.1 represents an unsubstituted or substituted, aliphatic, aromatic or heteroaromatic radical,alk represents an alkylene, alkenylene or alkylidene radical having a maximum of 5 carbon atoms,n.sub.1 represents 0, 1 or 2n.sub.2 represents 0 or 1,R.sub.2, R.sub.3 and R.sub.4 each represents, independently of the others, hydrogen, lower alkyl, lower alkoxy or halogen, andA represents the radical --O--R.sub.5, wherein R.sub.5 represents hydrogen or an unsubstituted or substituted, aliphatic or araliphatic hydrocarbon radical, or A represents the radical ##STR2## in which either R.sub.6 and R.sub.7 each represents, independently of the other, hydrogen or lower alkyl, or R.sub.6 and R.sub.

Abstract: The present invention relates to a novel process for the manufacture of 4-thioazetidinone compounds of the formula ##STR1## in which R.sub.1.sup.a represents an amino-protecting group and R.sub.1.sup.b represents hydrogen or an acyl radical Ac, or in which R.sub.1.sup.a and R.sub.1.sup.b together represent a bivalent acyl radical, R.sub.2.sup.A represents an etherified hydroxy group, R.sub.3 represents methyl, hydroxy, etherified or esterified hydroxy, cyano, tertiary amino or nitro, X represents hydrogen or halogen, and Y represents a group --SR.sub.4 or --SO.sub.2 --R.sub.5 in which R.sub.4 represents an optionally substituted heteroaryl radical or the acyl radical of an organic carboxylic or thiocarboxylic acid and R.sub.5 represents an optionally substituted hydrocarbon radical, or, when R.sub.3 represents hydroxy or methyl, tautomers thereof. Compounds of the formula I are manufactured by reacting compounds of the formula III with a nitrosating agent and a compound of the formula IV.

Abstract: The invention relates to novel antigen derivatives comprising an antigen and at least one muramylpeptide covalently bonded thereto, if appropriate via a spacer, to pharmaceutical preparations which contain such compounds and to their use as a vaccine.The novel antigen derivatives produce a pronounced increase in the immuno-response to the antigen, and in particular also a cell-medicated immunity under clinically acceptable conditions of administration.

Abstract: The invention relates to a process for the manufacture of the known 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine of the formula III which is characterized in that, for example, 5-cyano-5H-dibenz[b,f]azepine of the formula I is nitrated to form 5-cyano-10-nitro-5H-dibenz[b,f]azepine of the formula II, this is subjected to hydrolysis, then reduction, then the reduction product contained in the reaction mixture is subjected to hydrolysis and the end product of the formula III is isolated in pure form.The process is illustrated by the following reaction scheme: ##STR1## The invention relates also to new intermediates produced in these reactions.

Abstract: The invention relates to novel substituted phenyl ethers of the formula ##STR1## in which Ar represents a mono- or bi-cyclic carbocyclic aryl radical, or a mono- or bi-cyclic heterocyclic aryl radical bonded to a phenylene radical by way of a ring carbon atom,Ph represents a phenylene radical,n has the value 0 to 1 andalk represents alkylene having from 2 to 5 carbon atoms, the nitrogen atom and the oxygen atom or, if n is 0, the aromatic radical being separated from each other by at least two carbon atoms in the unbranched chain, andR.sub.1 and R.sub.2 each represents, independently of the other, hydrogen or lower alkyl, or together represent lower alkylene, oxa-lower alkylene, thia-lower alkylene, aza-lower alkylene or N-lower alkyl-aza-lower alkylene,and salts thereof, especially pharmaceutically acceptable non-toxic acid addition salts. Such compounds possess, on the one hand, blocking properties towards .beta.-adrenergic receptors and can therefore be used as .beta.

Abstract: Contact lenses comprising polymeric lens materials in which reactive dyestuffs have been covalently bonded to monomer units of the polymer backbone, said reactive dyestuffs being reactive dyes capable of forming ether linkages with cellulose and reactive with hydroxyl, amino, amido or mercapto groups present in a hydrogel polymer to form the covalent bond therewith. The invention is of particular interest in the area of so-called hydrophilic or "soft" contact lenses, commonly referred to as hydrogel lenses.

Abstract: Benzofurans or 2,3-dihydrobenzofurans of the formula ##STR1## in which R.sub.1 represents hydrogen or an aliphatic radical,R.sub.2 represents an amino group disubstituted by a bivalent aliphatic radical which is optionally interrupted by at least one hetero atom,and the aromatic ring may be additionally substituted,and the salts thereof, have anti-inflammatory and/or analgesic activities.

Abstract: Contact lenses comprising polymeric lens materials in which reactive dyestuffs have been covalently bonded to monomer units of the polymer backbone, said reactive dyestuffs being reactive dyes capable of forming either linkages with cellulose and reactive with hydroxyl, amino, amido or mercapto groups present in a hydrogel polymer to form the covalent bond therewith. The invention is of particular interest in the area of so-called hydrophilic or "soft" contact lenses, commonly referred to as hydrogel lenses.

Abstract: The invention relates to pharmaceutical preparations for topical application which contain salts of alkanecarboxylic acids, in particular compounds of the formula ##STR1## wherein R.sub.1 is a group of the formula ##STR2## wherein X.sub.1 and X.sub.2 are hydrogen and X.sub.3 is isobutyl, or X.sub.1 and X.sub.3 are hydrogen and X.sub.2 is benzoyl, or X.sub.1 is hydrogen, X.sub.2 is chlorine, and X.sub.3 is 3-pyrrolin-1-yl, or X.sub.1 is hydrogen, X.sub.2 is a group of the formula --CH.dbd.CH--C(OCH.sub.3).dbd.CH--X.sub.4, and X.sub.3 together with X.sub.4 are a bond, and R.sub.2 is methyl, or X.sub.2 and X.sub.3 are hydrogen and X.sub.1 is 2,6-dichloroanilino, and R.sub.2 is hydrogen, or R.sub.1 is a group of the formula ##STR3## wherein X.sub.5 is the common bond with the methine group in formula I, X.sub.6 and X.sub.7 are hydrogen, X.sub.8 is p-methylbenzoyl, Y is a nitrogen atom, and X.sub.9 is a methyl group, or X.sub.5 is a methyl group, X.sub.6 is a common bond with the methine group in formula I, X.sub.

Abstract: The invention concerns a process for the manufacture of 7.beta.-amino-3-cephem-3-ol-4-carboxylic acid compounds by ring closure of esters of 2-[4-(substituted-thio)-3-acylamino-2-oxoazetidin-1-yl]-3-substituted-amin o-crotonic acids and solvolysing the enamine group in the resulting 7.beta.-acylamino-3-substituted-amino-cephem-4-carboxylic acid esters.

Abstract: The compounds of the formula I ##STR1## in which each of R.sup.1, R.sup.4 and R.sup.6, independently of the others, represents hydrogen or lower alkanoyl, R.sup.2 represents C.sub.1-4 -alkyl, hydroxymethyl or phenyl, R.sup.3 represents hydrogen or methyl, R.sup.5 represents hydrogen or C.sub.1-3 -alkyl, R.sup.7 represents C.sub.1-3 -alkyl that is unsubstituted or substituted by hydroxy, mercapto or methylthio, R.sup.8 represents hydrogen or lower alkyl, X represents oxygen or the group NH, Y represents C.sub.1-4 -alkylidene, and each of R.sup.9 and R.sup.10, independently of the other, represents C.sub.11-17 -alkyl or C.sub.11-17 -alkenyl, and their salts, have an immunostimulating activeity.

Abstract: The invention relates to a process for the manufacture of the known 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,f]azepine of the formula III which is characterized in that, for example, 5-cyano-5H-dibenz[b,f]azepine of the formula I is nitrated to form 5-cyano-10-nitro-5H-dibenz[b,f]azepine of the formula II, this is subjected to hydrolysis, then reduction, then the reduction product contained in the reaction mixture is subjected to hydrolysis and the end product of the formula III is isolated in pure form.The process is illustrated by the following reaction scheme: ##STR1## The invention relates also to new intermediates produced in these reactions.

Abstract: 2-Penem-3-carboxylic acid compounds of the formula ##STR1## in which R.sub.1 represents hydrogen, an organic radical bonded by a carbon atom to the ring carbon atom or an etherified mercapto group andR.sub.2 represents hydroxy or a radical R.sub.2.sup.A forming together with the carbonyl grouping --C(.dbd.O)-- a protected carboxyl group,1-oxides thereof, as well as salts of such compounds having salt-forming groups, in racemic and optically active form, processes for their preparation, pharmaceutical compositions containing such compounds, and their use as antibiotics, and intermediates and their processes which are useful in the production of the compounds of the formula I.

Abstract: 2-Penem-3-carboxylic acid compounds of the formula ##STR1## in which R.sub.1 represents hydrogen, an organic radical bonded by a carbon atom to the ring carbon atom or an etherified mercapto group andR.sub.2 represents hydroxy or a radical R.sub.2.sup.A forming together with the carbonyl grouping --C(.dbd.O)--a protected carboxyl group,1-oxides thereof, as well as salts of such compounds having salt-forming groups, in racemic and optically active form, processes for their preparation, pharmaceutical compositions containing such compounds, and their use as antibiotics, and intermediates and their processes which are useful in the production of the compounds of the formula I.

Abstract: Disclosed is a new and distinct Spathiphyllum variety distinguished particularly by rapid growth, denser appearance and compact growth when compared to related plants. Spathe color is initially white turning a light green hue past maturity.

Abstract: Disclosed is a new and distinct variety of Spathiphyllum which is particularly distinguished by having rapid growth and a propensity to sucker as compared to related plants. The plant is a selection from the cross Mauna Loa `Alice`.times.floribundum (seed parent) and wallisi (pollen parent).